Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7602198 | 0.99 | HRH3 (0.36) | HRH3CYP19A1KCNK3KCNK9SMN1; SMN2 | |
| SCHEMBL7486094 | 0.88 | PRKAB2 (0.37) | HRH3CYP19A1KCNK3KCNK9SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7485157 | 0.88 | PRKAB2 (0.37) | HRH3KCNK3KCNK9SMN1; SMN2TSHR | |
| SCHEMBL7587917 | 0.85 | FNTA (0.41) | HRH3CYP19A1CYP2D6KDM1A | |
| SCHEMBL7186697 | 0.77 | FNTA (0.47) | — | |
| SCHEMBL7587632 | 0.77 | KMT2A (0.41) | SMN1; SMN2TSHRUSP2KDM4EALDH1A1 | |
| SCHEMBL7594805 | 0.76 | FASN (0.45) | SMN1; SMN2TSHRUSP2CYP2C9CYP1A2 | |
| SCHEMBL7481462 | 0.76 | PRKAA2 (0.39) | HRH3CYP19A1SMN1; SMN2ACACBUSP2 | |
| Hydrochloric Acid SCHEMBL7570753 | 0.76 | KMT2A (0.41) | SMN1; SMN2TSHRUSP2PRKAA2KDM4E | |
| SCHEMBL7543174 | 0.76 | FASN (0.38) | ACACBPRKAA2FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | claimed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | claimed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1165084-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1165084-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000051614-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | HRH3 4170/4885CYP19A1 2104/4885KCNK3 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.